



ViroGates announces a new clinical routine customer in Greece

3.3.2021 11:45:49 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 5-2021 - 3 March 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces a new hospital in Greece as a new clinical routine customer. ViroGates now has four clinical routine customers in Greece.

The new customer is a public hospital in the Athens area. The hospital has around 700 beds and is a pivotal hospital in the battle against the COVID-19 pandemic in the Athens area. The hospital will be using the suPARnostic® Quick Triage product and is one of the study sites in the previously announced SAVE-MORE study.

ViroGates serves all customers in Greece through an Athens-based Greek agent from the headquarter in Denmark. Due to the customers' internal policies, ViroGates cannot disclose the name of the hospital.

Jakob Knudsen, Chief Executive Officer of ViroGates, said: *"We are excited to welcome another Greek hospital as a clinical routine customer. The Greek market has started to adopt our products at an increasing pace based on the need for COVID-19 patient management and positive results from past local clinical studies within sepsis and other infectious medicine areas. Once again we experience that clinicians see a value in our products and are happy to share this with peers working in different hospitals in the area."*

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

Disclaimer

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20210303-ViroGates Company announcement 5.pdf](#)